trending Market Intelligence /marketintelligence/en/news-insights/trending/tdahwy8cqcgft5iqgbtzog2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us
In This List

Indivior loses patent suit to Alvogen for opioid addiction therapy


Needham & Company is Now Available in the S&P Global Market Intelligence Aftermarket Research Collection


Banking Essentials Newsletter - February Edition


Message in a (Word)Cloud

Six trends shaping the industries and sectors we cover in 2021

Indivior loses patent suit to Alvogen for opioid addiction therapy

Indivior PLC said a U.S. court found that privately held Alvogen, Inc. did not violate three of the patents related to its opioid addiction therapy, Suboxone Film.

The Richmond, Va.-based pharmaceutical company "believes that it has grounds to appeal" the U.S. District Court for the District of Delaware's ruling on the patents.

According to the company's 2017 annual report, Suboxone Film had an average market share of 57% in 2017, down from 61% in 2016.

Indivior added that if a generic version of Suboxone Film should be released in the U.S., "it could potentially result in a rapid and material loss of market share" for the medicine.

In February, Indivior filed lawsuits in the U.S. against generic-drug makers Dr. Reddy's Laboratories Ltd., Alvogen and Teva Pharmaceutical Industries Ltd. over a patent covering the opioid addiction treatment.